Aravive (ARAV) Issues Earnings Results, Beats Estimates By $0.44 EPS

Aravive (NASDAQ:ARAV) announced its earnings results on Wednesday, May 8th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.44, Fidelity Earnings reports. The company had revenue of $1.70 million during the quarter.

NASDAQ ARAV opened at $5.81 on Friday. Aravive has a fifty-two week low of $3.07 and a fifty-two week high of $15.30. The firm has a market capitalization of $65.54 million, a PE ratio of -0.55 and a beta of 2.47. The company has a quick ratio of 7.78, a current ratio of 7.78 and a debt-to-equity ratio of 0.17.

An institutional investor recently bought a new position in Aravive stock. Geode Capital Management LLC purchased a new position in Aravive Inc (NASDAQ:ARAV) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 29,959 shares of the company’s stock, valued at approximately $105,000. Geode Capital Management LLC owned about 0.27% of Aravive as of its most recent SEC filing. Hedge funds and other institutional investors own 27.57% of the company’s stock.

A number of analysts recently weighed in on the company. Piper Jaffray Companies assumed coverage on Aravive in a research note on Monday, May 13th. They issued an “overweight” rating and a $10.00 price target on the stock. Wedbush began coverage on Aravive in a research note on Monday, April 8th. They issued an “outperform” rating and a $14.00 price target on the stock.

WARNING: “Aravive (ARAV) Issues Earnings Results, Beats Estimates By $0.44 EPS” was originally reported by Rockland Register and is owned by of Rockland Register. If you are viewing this piece on another site, it was copied illegally and republished in violation of US & international copyright & trademark law. The correct version of this piece can be accessed at

Aravive Company Profile

Aravive, Inc, a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer.

Featured Article: What is a Fiduciary?

Earnings History for Aravive (NASDAQ:ARAV)

Receive News & Ratings for Aravive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aravive and related companies with's FREE daily email newsletter.